Denosumab biosimilar by Sandoz Group for Post Menopausal Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Post Menopausal Osteoporosis.

Study shows long COVID’s hidden effect on women’s sex lives

From work to school to socializing, COVID-19 has impacted just about every part of our lives-;and now Boston University research has shown that also includes

February 10, 2024

Brain’s waste removal route found in nasal lymphatics

In a groundbreaking study published in Nature, South Korean researchers led by Director KOH Gou Young of the Center for Vascular Research within the Institute

January 27, 2024

In a reality check for the field, AI underwhelms in Leash Bio’s binding contest: ‘No one did well’

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.